Standard-of-Care, Nonclinical Aspects, and Clinical Pharmacology
CML-CP
Current first-line treatment of CML-CP consists of TKIs such as imatinib, nilotinib, dasatinib, and bosutinib.In contrast to other TKIs, asciminib allosterically binds to the myristoyl pocket of the BCR-ABL1 protein, locking it into an inactive conformation without blocking the kinase ATP-binding site.